Concurrent Oncogene Mutation Profile in Chinese Patients With Stage Ib Lung Adenocarcinoma

Wen, Yang; Cai, Ling; Zhang, Xuewen; Zhu, Jianfei; Zhang, Zi-Chen; Shao, Jian Yong

doi:10.1097/md.0000000000000296

Cited by 20 publications

(18 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12 Even higher incidences were reported in smaller studied populations: 0.6% to 6.1% of lung cancers, 1.5% to 33% of EGFRmutated lung cancers, and 3.3% to 22% of KRAS-mutated lung cancers (Table 4). [30][31][32][33][34][35][36][37][38] Coexisting mutations were confirmed in 2 studies using the same or alternative assays, 30,35 and in this study using the original assay and an alternative assay to test DNA reisolated from new slides.…”

Section: Discussionmentioning

confidence: 53%

Clinical Validation of Coexisting Activating Mutations Within EGFR, Mitogen-Activated Protein Kinase, and Phosphatidylinositol 3-Kinase Pathways in Lung Cancers

Marchi

Haley

Fryer

et al. 2019

Archives of Pathology & Laboratory Medicine

View full text Add to dashboard Cite

Context.-Mutations within the same signature transduction pathway are redundant and, therefore, most are mutually exclusive. Laboratory errors, however, may introduce unexpected coexisting mutations. Objective.-To validate coexisting mutations within epidermal growth factor receptor (EGFR), mitogen-activated protein kinase, and phosphatidylinositol 3-kinase pathways. Design.-In this retrospective study for quality assessment of next-generation sequencing in a clinical diagnostics setting, coexisting mutations within EGFR, KRAS, NRAS, BRAF, AKT1, and PIK3CA genes were examined in 1208 non-small cell lung cancers. Results.-EGFR mutations did not coexist with BRAF mutations, neither kinase-activated nor kinase-impaired mutations. There was a low but similar incidence (3.3%-5.1%) of PIK3CA mutations in BRAF-, EGFR-, and KRASmutated lung cancers and a rare incidence of coexisting KRAS and EGFR mutations detected in 1 of 1208 lung cancers (0.08%) or 1 of 226 EGFR-mutated lung cancers

show abstract

Section: Discussionmentioning

confidence: 53%

Clinical Validation of Coexisting Activating Mutations Within EGFR, Mitogen-Activated Protein Kinase, and Phosphatidylinositol 3-Kinase Pathways in Lung Cancers

Marchi

Haley

Fryer

et al. 2019

Archives of Pathology & Laboratory Medicine

View full text Add to dashboard Cite

show abstract

“…EGFR mutations were present in 44.2% of tumors and involved in 10 of 13 co-mutated tumors. 7 Nevertheless, unlike our study, neither of these studies included ALK rearrangement and allowed analysis of either patient prognosis or response to targeted and conventional therapies. The Lung Cancer Mutation Consortium reported data on 1007 lung adenocarcinomas.…”

Section: Discussionmentioning

confidence: 92%

Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France

Guibert

Barlési

Descourt

et al. 2017

Journal of Thoracic Oncology

View full text Add to dashboard Cite

show abstract

“…Molecular characterization via MALDI-TOF on MassARRAY platform, which is characterized by high throughput, high sensitivity, and a simple operation, can be implemented by combining single-base extension and mass spectrometry technology. This approach also minimizes the weaknesses of traditional single-gene tests, such as high cost and their time-consuming and tedious procedures [8][9][10] . Given the short segments of the PCR amplification products, not only fresh tissue specimens but also formalin-fixed paraffin-embedded (FFPE) specimens, pleural effusion, and biopsy samples can be used for effective detection 3,4,8,9 .…”

Section: Discussionmentioning

confidence: 99%

“…Given the short segments of the PCR amplification products, not only fresh tissue specimens but also formalin-fixed paraffin-embedded (FFPE) specimens, pleural effusion, and biopsy samples can be used for effective detection 3,4,8,9 . LungCarta TM Panel, which is commercially available, can facilitate comprehensive screening of relevant biomarkers of lung cancer 4,10,11 . However, this method presents several limitations; for example, the panel is confidential.…”

Section: Discussionmentioning

confidence: 99%

“…A total of 13 target oncogenes (i.e. EGFR, KRAS, ALK, FGFR1, FGFR2, FGFR3, PIK3CA, BRAF, PTEN, MET, ERBB2, AKT1, and STK11), which were closely related to the pathogenesis, drug resistance, and metastasis of lung cancer and associated with relevant transduction pathways, were enrolled in the polygenic primer panel [5][6][7][8][9][10][11][12] .…”

Section: Determination Of Related Driver Genes Of Lung Cancermentioning

confidence: 99%

See 1 more Smart Citation

Establishment and application of a multiplex genetic mutation-detection method of lung cancer based on MassARRAY platform

Tian¹,

Zhang²,

Wang³

et al. 2016

Cancer Biology &Amp; Medicine

View full text Add to dashboard Cite

Objective: This study aims to establish a method for highly parallel multiplexed detection of genetic mutations in Chinese lung cancer samples through Agena iPLEX chemistry and matrix-assisted laser desorption ionization time-of-flight analysis on MassARRAY mass spectrometry platform. Methods:We reviewed the related literature and data on lung cancer treatments. We also identified 99 mutation hot spots in 13 target genes closely related to the pathogenesis, drug resistance, and metastasis of lung cancer. A total of 297 primers, composed of 99 paired forward and reverse amplification primers and 99 matched extension primers, were designed using Assay Design software. The detection method was established by analyzing eight cell lines and six lung cancer specimens. The proposed method was then validated through comparisons by using a LungCarta TM kit. The sensitivity and specificity of the proposed method were evaluated by directly sequencing EGFR and KRAS genes in 100 lung cancer cases. Results: The proposed method was able to detect multiplex genetic mutations in lung cancer cell lines. This finding was consistent with the observations on previously reported mutations. The proposed method can also detect such mutations in clinical lung cancer specimens. This result was consistent with the observations with LungCarta TM kit. However, an FGFR2 mutation was detected only through the proposed method. The measured sensitivity and specificity were 100% and 96.3%, respectively. Conclusions:The proposed MassARRAY technology-based multiplex method can detect genetic mutations in Chinese lung cancer patients. Therefore, the proposed method can be applied to detect mutations in other cancer tissues.

show abstract

Concurrent Oncogene Mutation Profile in Chinese Patients With Stage Ib Lung Adenocarcinoma

Abstract: Supplemental Digital Content is available in the text

Cited by 20 publications

References 27 publications

Clinical Validation of Coexisting Activating Mutations Within EGFR, Mitogen-Activated Protein Kinase, and Phosphatidylinositol 3-Kinase Pathways in Lung Cancers

Clinical Validation of Coexisting Activating Mutations Within EGFR, Mitogen-Activated Protein Kinase, and Phosphatidylinositol 3-Kinase Pathways in Lung Cancers

Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France

Establishment and application of a multiplex genetic mutation-detection method of lung cancer based on MassARRAY platform

Contact Info

Product

Resources

About